Potential new risk factors for ischemic stroke: What is their potential?

Stroke

Volumn 37, Issue 8, 2006, Pages 2181-2188

  Hankey, Graeme J ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cerebral infarct; Risk factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; PROTHROMBIN;

ALCOHOL CONSUMPTION; BODY MASS; BRAIN ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; DIETARY INTAKE; ENVIRONMENTAL FACTOR; EXERCISE; GENE DELETION; GENE INSERTION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART ATRIUM SEPTUM DEFECT; HEMOSTASIS; HUMAN; HYPERTENSION; INFECTION; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MENTAL STRESS; MICROALBUMINURIA; MONOCYTE; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VALVULAR HEART DISEASE; BRAIN ISCHEMIA;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HUMANS; RISK FACTORS;

EID: 33747158504     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000229883.72010.e4     Document Type: Review

References (82)

1. Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35:776-785.
2. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90|056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
3. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor W, Mayberg MR, Warlow CP, Barnett HJ, for the Carotid Endarterectomy Trialists' Collaboration. Pooled analysis of individual patient data from randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 2003;361:107-116.
4. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363:1491-1502.
5. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
6. Bonita R, Duncan J, Truelson T, Jackson R, Beaglehole R. Passive smoking as well as active smoking increases the risk of stroke. Tobacco Control. 1999;8:156-160.
7. Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 2004;27:2836-2842.
8. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-257.
9. Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. BMJ. 1970;32:26-34.
10. Kizer JR, Wiebers DO, Whisnant JP, Welty TK, Lee ET, Best LG, Resnick HE, Roman MJ, Devereaux RB. Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke. 2005;36:2533-2537.
11. Rodgers H, Greenaway J, Davies T, Wood R, Steen N, Thomson R. Risk factors for first-ever stroke in older people in the north east of England: a population-based study. Stroke. 2004;35:7-11.
12. Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke. BMJ. 2005;330:342-345.
13. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017-2023.
14. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
15. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;266:872-881.
16. Lawlor DA, Davey Smith G, Bruckdorfer R, Kundu D, Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet. 2004;363:1724-1727.
17. Whisnant JP. Modelling of risk factors for ischemic stroke: the Willis Lecture. Stroke. 1997;28:1840-1844.
18. Urban Hjorth JS. Computer Intensive Statistical Methods Validation Model Selection and Bootstrap. London, UK: Chapman and Hall; 1994.
19. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murrary CJL, and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
20. Ezzati M, Vander Hoorn S, Rodgers A, Lopez AD, Mathers CD, Murrary CJL, and the Comparative Risk Assessment Collaborating Group. Estimates of global and regional health gains from reducing multiple major risk factors. Lancet. 2003;362:271-280.
21. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211-1224.
22. Schulz UGR, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke. 2003;34:2050-2059.
23. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke. 2005;36:891-904.
24. Vasan RS, Sullivan LM, Wilson PWF, Sempos CT, Sundstrom J, Kannel WB, Levy D, D'Agostino RB. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med. 2005;142:393-402.
25. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
26. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777-780.
27. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375-3383.
28. Bhatia M, Howard SC, Clarke TG, Neale R, Qizilbash N, Murphy MFG, Rothwell PM. Apolipoproteins as predictors of ischemic stroke in patients with a previous transient ischemic attack. Cerebrovasc Dis. 2006;21:323-328.
29. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997;277:1539-1545.
30. Kurth T, Gaziano JM, Berger K, Case CS, Rexrode KM, Cook NR, Buring JE, Manson JE. Body mass index and the risk of stroke in men. Arch Intern Med. 2002;162:2557-2562.
31. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Elkind MS, Paik MC. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34:1586-1592.
32. Jood K, Jern C, Wilhelmsen L, Rosengren A. Body mass index in mid-life is associated with a first stroke in men: a prospective population study over 28 years. Stroke. 2004;35:2764-2769.
33. Song YM, Sung J, Smith GD, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke: a prospective study in Korean men. Stroke. 2004;35:831-836.
34. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003;34:2475-2481.
35. Hu G, Sarti C, Jousilahti P, Silventoinen K, Barengo NC, Tuomilehto J. Leisure time, occupational, and commuting physical activity and the risk of stroke. Stroke. 2005;36:1994-1999.
36. Dauchet L, Amouyel P, Dallongeville J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. Neurology. 2005;65:1193-1197.
37. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA. 2003;289:579-588.
38. Mukamal KJ, Ascherio A, Mittleman MA, Conigrave KM, Camargo CA Jr, Kawachi I, Stampfer MJ, Willett WC, Rimm EB. Alcohol and risk of ischemic stroke in men: the role of drinking patterns and usual beverage. Ann Intern Med. 2005;142:11-19.
39. Naimi TS, Brown DW, Brewer RD, Giles WH, Mensah G, Serdula MK, Mokdad AH, Hungerford DW, Lando J, Naimi S, Stroup DF. Cardiovascular risk factors and confounders among non-drinking and moderate-drinking U.S. adults. Am J Prev Med. 2005;28:369-373.
40. House A, Dennis M, Mogridge L, Hawton K, Warlow C. Life events and difficulties preceding stroke. J Neurol Neurosurg Psychiatry. 1990;53:1024-1028.
41. Simons LA, McCallum J, Friedlander Y, Simons J. Risk factors for stroke: Dubbo Study of the Elderly. Stroke. 1998;29:1341-1346.
42. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290:932-940.
43. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:216-229.
44. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109[suppl IV]:IV-6-IV-19.
45. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004;109[suppl IV]:IV-31-IV-46.
46. Bhatia M, Rothwell PM. A systematic comparison of the quality and volume of published data available on novel risk factors for stroke versus coronary heart disease. Cerebrovasc Dis. 2005;20:180-186.
47. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain. 2000;123:1784-1812.
48. Schulz UGR, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke. 2004;35:819-825.
49. Flossmann E, Rothwell PM. Family history of stroke in patients with transient ischemic attack in relation to hypertension and other intermediate phenotypes. Stroke. 2005;36:830-835.
50. Flossmann E, Schulz UGR, Rothwell PM. Potential confounding by intermediate phenotypes in studies of the genetics of ischaemic stroke. Cerebrovasc Dis. 2005;19:1-10.
51. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18000 cases and 58000 controls. Arch Neurol. 2004;61:1652-1662.
52. Lalouschek W, Schillinger M, Hsieh K, Endler G, Tentschert S, Lang W, Cheng S, Mannhalter C. Matched case-control study on Factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke. 2005;36:1405-1409.
53. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224-232.
54. Staton JM, Sayer MS, Hankey GJ, Attia J, Thakkinstian A, Yi Q, Cole VJ, Baker R, Eikelboom JW. Association between phosphodiesterase 4D gene and ischemic stroke. J Neurol Neurosurg Psych. 2006; In press.
55. Helgadottir A, Gretarsdottir S, St. Clair D, Manolescu A, Cheung J, Thorleifsson G, Pasdar A, Grant SF, Whalley LJ, Hakonarson H, Thorsteindottir U, Kong A, Gulcher J, Stefansson K, MacLeod MJ. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet. 2005;76:505-509.
56. Meschia JF, Brott TG, Brown RD Jr, Crook R, Worrall BB, Kissela B, Brown WM, Rich SS, Case LD, Evans EW, Hague S, Singleton A, Hardy J; SWISS Study Group; ISGS Study Group; MSGD Study Group. Phosphodiesterase 4D and 5-lipoxygenase-activating protein in ischemic stroke. Ann Neurol. 2005;58:351-361.
57. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin and leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA. 1998;279:1477-1482.
58. Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, Hacke W. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke. 2004;35:1147-1152.
59. Johnsen SH, Fosse E, Joakimsen O, Mathiesen EB, Arnesen E, Njolstad I. Monocyte count is a predictor of novel plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline: the Tromsø study. Stroke. 2005;36:715-719.
60. Torres JL, Ridker PM. Clinical use of high-sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003;18:471-478.
61. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. Stroke. 2001;32:2575-2579.
62. Lindsberg P, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34:2518-2532.
63. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies. J Clin Pathol. 1998;51:793-797.
64. Wells BJ, Mainous AG, Dickerson LM. Antibiotics for the secondary prevention of ischemic heart disease. Arch Intern Med. 2004;164:2156-2161.
65. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637-1645.
66. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646-1654.
67. Danesh J. Antibiotics in the prevention of heart attacks. Lancet. 2005;365:365-367.
68. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35:2300-2305.
69. Hankey GJ. Is homocysteine a modifiable risk factor for stroke? Nat Clin Pract Neurol. 2006;2:26-33.
70. Davey Smith G, Ebrahim S. Folate supplementation and cardiovascular disease. Lancet. 2005;366:1679-1681.
71. B-vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151:282-287.
72. Miettinen J, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27:2033-2039.
73. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients; Losaran Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2005;45:198-202.
74. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick D, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
75. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55:1172-1179.
76. Petty GW, Khanderia BK, Meissner I, Whisnant JP, Rocca WA, Christianson TJ, Sicks JD, O'Fallon WM, McClelland RL, Wiebers DO. A population-based study of the relationship between patent foramen ovale and cerebrovascular ischaemic events. Mayo Clin Proc. 2006;81:602-608.
77. Saver JL, Carroll JD, Hijazi ZM, et al. Randomised evaluation of Recurrent Stroke comparing PFO closure to Established Current standard of care Treatment (RESPECT): ongoing clinical trial abstracts. International Stroke Conference, 2005, American Stroke Association, CTP42. February 2-4, 2005; New Orleans, Louisiana, USA.
78. Mattle HP, Meier B, Windecker S. PC-trial-Patent foramen ovale and Cryptogenic embolism: ongoing clinical trial abstracts. International Stroke Conference, 2005, New Orleans, La, CTP55.
79. Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyond equipoise. JAMA. 2005;294:366-369.
80. Vivanco F, Martin-Ventura JL, Duran MC, Barderas MG, Blanco-Colio L, Darde VM, Mas S, Meilhac O, Michel JB, Tunon J, Egido J. Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res. 2005;4:1181-1191.
81. Ginsgurg GS, Donahue MP, Newby PK. Prospects of personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiol. 2005;46:1615-1627.
82. Hubner N, Yagil C, Yagil Y. Novel integrative approaches to the identification of candidate genes in hypertension. Hypertension. 2006;47:1-5.